Olaparib
Generic Details
Generic Name
Olaparib
Other Names
- Lynparza
Drug Class
- Poly(ADP-ribose) polymerase (PARP) inhibitor
Chemical Formula
C24H23FN4O3
Molecular Weight
434.47 g/mol
Mechanism of Action
- Inhibitor of poly ADP-ribose polymerase (PARP) enzymes, resulting in the trapping of PARP on DNA single-strand breaks, leading to cytotoxicity.
Indications
- Ovarian cancer
- Breast cancer
- Pancreatic cancer
- Prostate cancer
Common Dosage Forms
- Tablet
- Capsule
Typical Dosage
- 300 mg twice daily
Pediatric Dosage
- Safety and efficacy not established in pediatric patients.
Geriatric Dosage
- Adjust dosage based on individual patient requirements and renal function.
Side Effects
- Nausea
- Fatigue
- Anemia
- Vomiting
- Diarrhea
- Headache
Contraindications
- Hypersensitivity to olaparib or any component of the formulation
Pregnancy Category
- D - Use in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation Safety
- Not recommended during breastfeeding.
Drug Interactions
- Strong CYP3A4 and CYP2D6 inhibitors may increase olaparib concentrations
Overdose Symptoms
- Increased risk of severe myelosuppression
Antidote for Overdose
- No specific antidote, manage with supportive care and monitoring
Storage Conditions
- Store at room temperature, protect from moisture and light
Pharmacokinetics
- Absorption: Rapidly absorbed after oral administration
- Distribution: Extensively distributed, primarily bound to plasma proteins
- Metabolism: Primarily metabolized in the liver via CYP3A4 and CYP2D6 enzymes
- Excretion: Mainly excreted in feces and urine
Precautions
- Monitor blood counts regularly due to the risk of myelosuppression
Warnings
- May cause myelodysplastic syndrome or acute myeloid leukemia
- May increase the risk of developing secondary malignancies
Others
- May cause pneumonitis, embryotoxic and teratogenic potential